


GroupLine

News and updates for advisors
and plan sponsors



DRUGS Jan 4, 2021

20-43

Alberta Health implements biosimilar initiative

Alberta Health has introduced a biosimilar initiative intended to increase the uptake of biosimilar drugs for certain conditions.

To continue to receive coverage from Alberta Health, residents taking certain biologic drugs will be required to switch to a biosimilar drug by **Jan. 15, 2021**, unless they receive an exception from the province.

Impact to group drug plans

Canada Life supports Alberta Health's approach to biosimilar drugs, and we'll align our adjudication practices as closely as possible with the new process.

Beginning Jan. 15, 2021, we'll be working with affected plan members to ensure they're switching over to the biosimilar product, where applicable, to align with the province. First, we'll start with Alberta residents age 65 and over, then we'll work to transition residents under age 65 in additional phases.

What's next?

We'll continue to monitor provincial handling in Canada and adjust our adjudication practices as needed.

For more information

Please contact your Canada Life group representative.

The content of this GroupLine is for general use and informational purposes only. It is not intended to be legal or tax advice. The content of this GroupLine is based on information available at the time of publication, which is subject to change. Efforts have been made to ensure the accuracy of the information contained in this GroupLine. However, it may contain errors or omissions or become out of date following publication.